(Phe2,Orn8)-Oxytocin is a modified analog containing phenylalanine and ornithine substitutions that enhance structural diversity. The changes influence hydrophobic packing and electrostatic interactions at key positions. This analog supports detailed evaluation of oxytocin receptor preference and peptide conformation. Researchers frequently use it to explore structure-activity relationships within cyclic neuropeptides.
CAT No: O06016
CAS No:2480-41-3
Synonyms/Alias:Oxytocin, phe(2)-orn(8)-;PI Ornipressin;2480-41-3;2-Phe-8-orn-oxytocin;POOT;(2S)-N-[(2S)-4-amino-1-[[(2R)-1-[(2S)-2-[[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylidenepropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]pentanediamide;Oxytocin, phenylalanyl(2)-ornithine(8)-;Oxytocin, 2-L-phenylalanine-8-L-ornithine-;DTXSID20179500;SCHEMBL15512342;DTXCID10101991;DA-48758;(Phe2,Orn8)-Oxytocin trifluoroacetate salt;
3. The spatiotemporal control of signalling and trafficking of the GLP-1R
4. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More